BR9407812A - Compostos uso e processo de preparação dos mesmos composições farmacêuticas uso das mesmas e processo de tratamento de ataques distúrbios neurológicos e/ou condições nas quais há dano neurológico nos animais incluindo seres humanos - Google Patents

Compostos uso e processo de preparação dos mesmos composições farmacêuticas uso das mesmas e processo de tratamento de ataques distúrbios neurológicos e/ou condições nas quais há dano neurológico nos animais incluindo seres humanos

Info

Publication number
BR9407812A
BR9407812A BR9407812A BR9407812A BR9407812A BR 9407812 A BR9407812 A BR 9407812A BR 9407812 A BR9407812 A BR 9407812A BR 9407812 A BR9407812 A BR 9407812A BR 9407812 A BR9407812 A BR 9407812A
Authority
BR
Brazil
Prior art keywords
alkyl
halo
cyano
hydroxy
optionally substituted
Prior art date
Application number
BR9407812A
Other languages
English (en)
Portuguese (pt)
Inventor
Bruce Jeremy Sargent
David John Heal
Fernandez Maria Isab Fernandez
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of BR9407812A publication Critical patent/BR9407812A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
BR9407812A 1993-10-13 1994-10-12 Compostos uso e processo de preparação dos mesmos composições farmacêuticas uso das mesmas e processo de tratamento de ataques distúrbios neurológicos e/ou condições nas quais há dano neurológico nos animais incluindo seres humanos BR9407812A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321162A GB9321162D0 (en) 1993-10-13 1993-10-13 Therapeutic agents
PCT/EP1994/003364 WO1995010521A1 (en) 1993-10-13 1994-10-12 Therapeutic agents

Publications (1)

Publication Number Publication Date
BR9407812A true BR9407812A (pt) 1997-05-06

Family

ID=10743505

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9407812A BR9407812A (pt) 1993-10-13 1994-10-12 Compostos uso e processo de preparação dos mesmos composições farmacêuticas uso das mesmas e processo de tratamento de ataques distúrbios neurológicos e/ou condições nas quais há dano neurológico nos animais incluindo seres humanos

Country Status (31)

Country Link
US (1) US5753665A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0723546B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH09503771A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1040537C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE188966T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU679573B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG62405B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9407812A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2173857A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ106996A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69422724T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0723546T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2142413T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI961630A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB9321162D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3032480T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT74580A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL111259A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN179169B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY112110A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO306509B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ274500A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL177920B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT723546E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO117020B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2136684C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK282329B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW372237B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA42738C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1995010521A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA947949B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506382D0 (en) * 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
GB9507348D0 (en) * 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
US5714607A (en) * 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
KR20000029548A (ko) 1996-07-25 2000-05-25 더블유. 지. 콜 가바수용체에대한리간드로서의치환된트리아졸로-피리다진유도체
GB9617727D0 (en) * 1996-08-23 1996-10-02 Knoll Ag Process
GB9626746D0 (en) * 1996-12-23 1997-02-12 Knoll Ag Process
DE19706336A1 (de) * 1997-02-19 1998-08-20 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Alkoholen
DE19706337A1 (de) * 1997-02-19 1998-08-20 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Estern
DE19707008A1 (de) * 1997-02-21 1998-08-27 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Alkoholen
WO2000023449A1 (en) * 1998-10-16 2000-04-27 Merck Sharp & Dohme Limited Pyrazolo-triazine derivatives as ligands for gaba receptors
GB9906124D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Therapeutic agent
GB9906130D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Compounds for use in therapy
GB9906126D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Pharmaceutical formulations
GB9914743D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
GEP20053688B (en) * 2000-06-30 2005-12-12 Wyeth Corp Substituted-Triazolopyrimidines as Anticancer Agents
TWI334868B (en) * 2003-06-03 2010-12-21 Nippon Kayaku Kk [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof
BRPI0507670A (pt) 2004-02-13 2007-07-17 Warner Lambert Co moduladores do receptor de androgênio
WO2005100305A1 (en) 2004-04-13 2005-10-27 Warner-Lambert Company Llc Androgen modulators
EP1740533A1 (en) 2004-04-22 2007-01-10 Warner-Lambert Company LLC Androgen modulators
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
AU2009285533B2 (en) * 2008-08-29 2014-02-13 Concert Pharmaceuticals Inc. Substituted triazolo-pyridazine derivatives
US8685987B2 (en) 2009-04-01 2014-04-01 Ataxion, Inc. Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators
WO2010112484A1 (en) * 2009-04-01 2010-10-07 Neurosearch A/S SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
DK2414365T3 (da) * 2009-04-01 2014-03-31 Aniona Aps SUBSTITUEREDE [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINER OG ANVENDELSE HERAF SOM KALIUMKANALMODULATORER
US11814734B2 (en) 2019-05-13 2023-11-14 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE46306B1 (en) * 1977-02-11 1983-05-04 Ici Ltd Safeguarded toxic chemical compositions containing an emetic
FR2549834B1 (fr) * 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
WO1989001478A1 (en) * 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
US5387747A (en) * 1992-02-24 1995-02-07 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present

Also Published As

Publication number Publication date
DE69422724T2 (de) 2000-09-07
JPH09503771A (ja) 1997-04-15
EP0723546B1 (en) 2000-01-19
FI961630A0 (fi) 1996-04-12
RO117020B1 (ro) 2001-09-28
DE69422724D1 (de) 2000-02-24
SK282329B6 (sk) 2002-01-07
US5753665A (en) 1998-05-19
WO1995010521A1 (en) 1995-04-20
RU2136684C1 (ru) 1999-09-10
CN1040537C (zh) 1998-11-04
DK0723546T3 (da) 2000-05-01
FI961630A7 (fi) 1996-04-12
HUT74580A (en) 1997-01-28
GR3032480T3 (en) 2000-05-31
IL111259A0 (en) 1995-03-30
IL111259A (en) 1998-02-08
CA2173857A1 (en) 1995-04-20
NO961435D0 (no) 1996-04-11
MY112110A (en) 2001-04-30
NO961435L (no) 1996-06-10
UA42738C2 (uk) 2001-11-15
NO306509B1 (no) 1999-11-15
PL313970A1 (en) 1996-08-05
PT723546E (pt) 2000-04-28
AU7855494A (en) 1995-05-04
ZA947949B (en) 1996-01-23
IN179169B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-09-06
NZ274500A (en) 1997-06-24
SK43796A3 (en) 1996-10-02
EP0723546A1 (en) 1996-07-31
TW372237B (en) 1999-10-21
BG62405B1 (bg) 1999-10-29
BG100485A (bg) 1996-11-29
PL177920B1 (pl) 2000-01-31
ES2142413T3 (es) 2000-04-16
CN1135754A (zh) 1996-11-13
ATE188966T1 (de) 2000-02-15
HU9600959D0 (en) 1996-06-28
CZ106996A3 (en) 1996-09-11
AU679573B2 (en) 1997-07-03
GB9321162D0 (en) 1993-12-01

Similar Documents

Publication Publication Date Title
BR9407812A (pt) Compostos uso e processo de preparação dos mesmos composições farmacêuticas uso das mesmas e processo de tratamento de ataques distúrbios neurológicos e/ou condições nas quais há dano neurológico nos animais incluindo seres humanos
DE3774398D1 (de) Mittel zur verbesserung der perkutanen absorption, diese enthaltende arzneimittel und methode zu ihrer verwendung.
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
NO990088L (no) Farmas°ytiske preparater omfattende S-(-)-N-propargyl-1-aminoindamin
TR200002567T2 (tr) Glisin naklini önleyiciler.
HRP20060278B1 (hr) 6-0-supstituirani ketolidi antibakterijskog djelovanja
MY133027A (en) C-4"-substituted macrolide derivatives
RU94022743A (ru) Амидо- или карбамидо-производные, обладающие антигиперхолестериновой активностью, и фармацевтическая композиция на их основе
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
NO951797D0 (no) Terapeutiske midler
KR970705392A (ko) 신규한 항생제 조성물 및 그람-양성 세균 및 마이코플라스마 감염의 치료 방법(novel antibiotic compounds and methods to treat grampositive bacterial and mycoplasmal infections)
CA2148194A1 (en) Cyclopeptides of the formula i
BR9903737A (pt) Carbamatos em c-11 de macrólidos antibacterianos
GB9418912D0 (en) Pharmaceutically active compounds
AR032653A1 (es) Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
RU93004678A (ru) Противомикробные производные карбапенема, способы их получения и применение
PL308667A1 (en) Neuroprotective 3,4-dihydro-2(1h)-quinolonic compounds
GR3036008T3 (en) Use of macrolides for the treatment of cerebral ischemia.
WO2001032650A3 (en) Alkaline salts of n-(6-alkyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinesulfone)-n'-isonicotinoylhydrazide, possess for their preparation, and pharmaceutical composition based on these salts
MXPA01009384A (es) Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina.
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção
KR900007844A (ko) 2-[4-(n-시아노 설파모일메틸)-1-피리디늄]에틸티오 카바페넴
JO1833B1 (en) Therapeutic agents
Prahlad et al. Actinomycin D: Effect on induced metamorphosis in the Mexican axolotl
GEP19971029B (en) Antiviral or antibacterial compound and method of use thereof

Legal Events

Date Code Title Description
FA Application withdrawn